See more : Shield Therapeutics plc (SHIEF) Income Statement Analysis – Financial Results
Complete financial analysis of Cisen Pharmaceutical Co., Ltd. (603367.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cisen Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Wingara AG Limited (WNR.AX) Income Statement Analysis – Financial Results
- MHM Automation Limited (MHM.NZ) Income Statement Analysis – Financial Results
- AI TRANSPORTATION ACQUISITION CORP Unit (AITRU) Income Statement Analysis – Financial Results
- Zonetail Inc. (ZONE.V) Income Statement Analysis – Financial Results
- Lime Chemicals Limited (LIMECHM.BO) Income Statement Analysis – Financial Results
Cisen Pharmaceutical Co., Ltd. (603367.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lkcisen.com
About Cisen Pharmaceutical Co., Ltd.
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells chemical drug preparations and health care products in China and internationally. The company's chemical drug preparations include liver disease drugs, antitumor and auxiliary drugs, nutrition preparations, contrast agents, antibiotics, digestive system agents, polypropylene ampoules, and external preparations, as well as sedation anesthesia, cardiovascular, cough and asthma, immunomodulator, infusion, and therapeutic infusion products. The company was formerly known as Shandong Lukang Cisen Pharmaceutical Co., Ltd. and changed its name to Cisen Pharmaceutical Co., Ltd. in 2011. Cisen Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Jining, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.46B | 4.07B | 3.78B | 3.67B | 4.11B | 3.81B | 2.96B | 2.56B | 2.50B | 2.39B | 2.21B | 2.05B | 1.53B |
| Cost of Revenue | 1.84B | 1.79B | 1.68B | 1.57B | 1.75B | 1.62B | 1.45B | 1.50B | 1.58B | 1.52B | 1.40B | 1.21B | 920.70M |
| Gross Profit | 2.62B | 2.28B | 2.10B | 2.10B | 2.36B | 2.19B | 1.51B | 1.07B | 921.06M | 866.12M | 805.47M | 837.68M | 610.72M |
| Gross Profit Ratio | 58.79% | 55.99% | 55.46% | 57.24% | 57.43% | 57.41% | 51.08% | 41.54% | 36.89% | 36.26% | 36.51% | 40.83% | 39.88% |
| Research & Development | 377.96M | 335.17M | 334.35M | 309.58M | 310.56M | 325.98M | 142.00M | 108.69M | 103.82M | 135.03M | 123.98M | 97.52M | 0.00 |
| General & Administrative | 98.08M | 85.16M | 69.78M | 54.39M | 64.36M | 55.76M | 50.95M | 41.04M | 39.02M | 31.42M | 223.57M | 166.72M | 121.78M |
| Selling & Marketing | 1.33B | 1.31B | 1.25B | 1.18B | 1.30B | 1.09B | 760.81M | 469.87M | 342.04M | 331.30M | 328.03M | 307.37M | 197.96M |
| SG&A | 1.43B | 1.39B | 1.32B | 1.24B | 1.37B | 1.15B | 811.76M | 510.91M | 381.06M | 362.72M | 551.60M | 474.10M | 319.74M |
| Other Expenses | -23.89M | 192.63M | 160.53M | 133.05M | 146.38M | 2.37M | 6.36M | 19.81M | 19.42M | 17.18M | 31.93M | 8.96M | 7.37M |
| Operating Expenses | 2.03B | 1.92B | 1.81B | 1.68B | 1.82B | 1.61B | 1.07B | 756.92M | 607.14M | 588.26M | 569.12M | 488.16M | 331.18M |
| Cost & Expenses | 3.87B | 3.71B | 3.50B | 3.25B | 3.58B | 3.24B | 2.52B | 2.26B | 2.18B | 2.11B | 1.97B | 1.70B | 1.25B |
| Interest Income | 41.59M | 34.32M | 17.67M | 9.72M | 4.57M | 5.06M | 5.54M | 7.78M | 2.21M | 891.63K | 0.00 | 1.07M | 0.00 |
| Interest Expense | 8.46M | 4.29M | 6.10M | 9.80M | 264.02K | 0.00 | 5.19M | 6.58M | 7.70M | 7.42M | 5.22M | 287.53K | 0.00 |
| Depreciation & Amortization | 235.84M | 231.23M | 222.63M | 159.98M | 164.18M | 177.81M | 188.08M | 54.47M | 193.03M | 171.60M | 48.16M | 46.03M | 18.39M |
| EBITDA | 840.03M | 604.30M | 562.56M | 655.58M | 746.86M | 745.57M | 618.34M | 365.37M | 469.30M | 430.55M | 236.35M | 349.52M | 288.58M |
| EBITDA Ratio | 18.82% | 15.75% | 15.74% | 18.01% | 18.39% | 20.96% | 21.60% | 20.32% | 21.09% | 19.17% | 11.61% | 18.16% | 18.84% |
| Operating Income | 592.58M | 364.58M | 334.42M | 484.67M | 582.71M | 565.61M | 416.21M | 269.61M | 270.00M | 241.58M | 208.06M | 326.48M | 270.19M |
| Operating Income Ratio | 13.28% | 8.97% | 8.84% | 13.19% | 14.17% | 14.85% | 14.05% | 10.51% | 10.81% | 10.11% | 9.43% | 15.91% | 17.64% |
| Total Other Income/Expenses | 3.28M | 1.61M | 1.71M | -156.68K | -603.77K | 2.37M | 6.36M | 18.93M | 15.42M | 24.32M | 31.16M | 5.73M | 7.49M |
| Income Before Tax | 595.86M | 366.19M | 336.13M | 484.52M | 582.11M | 567.98M | 422.56M | 289.20M | 285.41M | 256.39M | 239.22M | 335.37M | 277.68M |
| Income Before Tax Ratio | 13.35% | 9.01% | 8.89% | 13.19% | 14.15% | 14.92% | 14.26% | 11.28% | 11.43% | 10.73% | 10.84% | 16.35% | 18.13% |
| Income Tax Expense | 70.43M | 13.81M | 2.23M | 47.16M | 67.32M | 64.92M | 56.89M | 44.57M | 39.79M | 37.45M | 32.19M | 51.51M | 40.76M |
| Net Income | 521.34M | 349.96M | 334.15M | 438.78M | 514.58M | 503.54M | 367.22M | 246.88M | 246.85M | 220.15M | 208.30M | 283.86M | 236.93M |
| Net Income Ratio | 11.68% | 8.61% | 8.83% | 11.94% | 12.51% | 13.22% | 12.40% | 9.63% | 9.89% | 9.22% | 9.44% | 13.84% | 15.47% |
| EPS | 1.15 | 0.78 | 0.74 | 0.97 | 1.14 | 1.11 | 0.97 | 0.70 | 0.70 | 0.62 | 0.65 | 0.88 | 0.74 |
| EPS Diluted | 1.15 | 0.78 | 0.74 | 0.97 | 1.14 | 1.11 | 0.97 | 0.70 | 0.70 | 0.62 | 0.65 | 0.88 | 0.74 |
| Weighted Avg Shares Out | 453.34M | 451.34M | 449.83M | 452.36M | 453.35M | 453.35M | 378.58M | 352.69M | 352.65M | 355.08M | 353.05M | 354.82M | 355.08M |
| Weighted Avg Shares Out (Dil) | 453.34M | 451.34M | 449.83M | 452.36M | 453.35M | 453.64M | 378.58M | 352.69M | 352.65M | 355.08M | 355.08M | 355.08M | 355.08M |
Source: https://incomestatements.info
Category: Stock Reports